Navigation Links
Buckyballs used as 'passkey' into cancer cells

Scientists at Rice University and pediatric specialists at Baylor College of Medicine have discovered a new way to use Rice's famed buckyball nanoparticles as passkeys that allows drugs to enter cancer cells.

The research appears in the Jan. 21 issue of the journal Organic and Biomolecular Chemistry.

All living cells defend themselves by walling off the outside world. Cell walls, or membranes, form a protective cocoon around the cell's inner machinery and its DNA blueprints.

"Drugs are far more effective if they're delivered through the membrane, directly into the cell," said lead researcher Andrew Barron. "Viruses, which are often toxic, long ago developed ways of sneaking through cell walls. While we're mimicking some techniques used by viruses, we're using non-toxic pieces of protein, and we're incorporating buckyballs as a passkey."

The passkeys that Barron and colleagues developed contain a molecule called Bucky amino acid that was created in Barron's lab. Bucky amino acid, or Baa, is based on pheylalanine, one of the 20 essential amino acids that are strung together like beads on a necklace to build all proteins.

Barron's graduate student, Jianzhong Yang, developed several different Baa-containing peptides, or slivers of protein containing about a dozen or so amino acids. In their natural form, with pheylalanine as a link in their chain, these peptides did not pass through the cell walls.

Barron's group collaborated with Yang's brother, Baylor College of Medicine assistant professor Jianhua Yang at Texas Children's Cancer Center, and found the Baa-containing peptides could mimick viral proteins and pass through the walls of cancer cells. The peptides were found effective at penetrating the defenses of both liver cancer cells and neuroblastoma cells.

"Neuroblastoma is the most common extracranial solid tumor in children, and it is responsible for about 15 percent of pediatric cancer deaths," sai d Jianhua Yang. "Our findings are significant because neuroblastoma cells are well-known for their difficulty in transfection through the cell membrane."

Barron is Rice's Charles W. Duncan Jr.-Welch Professor of Chemistry, professor of materials science and associate dean for industry interactions and technology transfer.

Source:Rice University

Related biology news :

1. Buckyballs boost antibodys chemotherapy payload
2. Viral DNA sequence a possible trigger for breast cancer
3. Enzyme, lost in most mammals, is shown to protect against UV-induced skin cancer
4. Its not all genetic: Common epigenetic problem doubles cancer risk in mice
5. Columbia research lifts major hurdle to gene therapy for cancer
6. Combination therapy boosts effectiveness of telomere-directed cancer cell death
7. Mitochondrial DNA mutations play significant role in prostate cancer
8. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
9. BRCA1 causes ovarian cancer through indirect, biochemical route
10. Researchers identify target for cancer drugs
11. Weizmann Institute scientists develop a new approach for directing treatment to metastasized prostate cancer in the bones.

Post Your Comments:

(Date:11/17/2015)... Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and ... of broadly enabling, pressure cycling technology ("PCT")-based sample preparation ... it has received gross proceeds of $745,000 from an ... "Offering"), increasing the total amount raised to date in ... are expected in the near future. ...
(Date:11/12/2015)... , Nov. 12, 2015  Arxspan has entered ... MIT and Harvard for use of its ArxLab ... management tools. The partnership will support the institute,s ... and chemical research information internally and with external ... used for managing the Institute,s electronic laboratory notebook, ...
(Date:11/10/2015)... 10, 2015  In this report, the ... of product, type, application, disease indication, and ... report are consumables, services, software. The type ... biomarkers, efficacy biomarkers, and validation biomarkers. The ... diagnostics development, drug discovery and development, personalized ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... , Nov. 25, 2015  PharmAthene, Inc. (NYSE ... has adopted a stockholder rights plan (Rights Plan) in ... operating loss carryforwards (NOLs) under Section 382 of the ... --> PharmAthene,s use of its NOLs could ... change" as defined in Section 382 of the Code. ...
(Date:11/25/2015)... CITY , Nov. 25, 2015 /PRNewswire/ - Aeterna ... affirms that its business and prospects remain fundamentally ... , Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation ... to completion following review of the final interim ... Phase 2 Primary Endpoint in men with heavily ...
(Date:11/24/2015)... Malaysia , Nov. 24, 2015  Asia-Pacific ... contract research organisation (CRO) market. The trend of ... in lower margins but higher volume share for ... capacity and scale, however, margins in the CRO ... Organisation (CRO) Market ( ), finds ...
(Date:11/24/2015)... Mass. (PRWEB) , ... November 24, 2015 , ... ... to maintain healthy metabolism. But unless it is bound to proteins, copper is ... of Health (NIH), researchers at Worcester Polytechnic Institute (WPI) will conduct a systematic ...
Breaking Biology Technology: